CompletedPhase 1NCT00473135

Safety of and Immune Response of a 2-dose Regimen of rDEN1delta30 Dengue Virus Vaccine

Studying Dengue fever

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Principal Investigator
Anna Durbin, MD, MD
Center for Immunization Research (CIR), Johns Hopkins School of Public Health
Intervention
rDEN1delta30(biological)
Enrollment
60 enrolled
Eligibility
18-50 years · All sexes
Timeline
2007

Study locations (1)

Collaborators

Johns Hopkins Bloomberg School of Public Health

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00473135 on ClinicalTrials.gov

Other trials for Dengue fever

Additional recruiting or active studies for the same condition.

See all trials for Dengue fever →

← Back to all trials